\begin{thebibliography}{130}
\providecommand{\natexlab}[1]{#1}
\providecommand{\url}[1]{\texttt{#1}}
\expandafter\ifx\csname urlstyle\endcsname\relax
  \providecommand{\doi}[1]{doi: #1}\else
  \providecommand{\doi}{doi: \begingroup \urlstyle{rm}\Url}\fi

\bibitem[Gideon~Gross(1989)]{first}
Zelig~Eshhar Gideon~Gross, Tova~Waks.
\newblock Expression of immunoglobulin-t-cell receptor chimeric molecules as
  functional receptors with antibody-type specificity.
\newblock \emph{Proc Natl Acad Sci USA}, 86\penalty0 (24):\penalty0
  10024–10028, 1989.

\bibitem[Kuwana et~al.(1987)Kuwana, Asakura, Utsunomiya, Nakanishi, Arata,
  Itoh, Nagase, and Kurosawa]{KUWANA1987960}
Yoshihisa Kuwana, Yoshihiro Asakura, Naoko Utsunomiya, Mamoru Nakanishi, Yohji
  Arata, Seiga Itoh, Fumihiko Nagase, and Yoshikazu Kurosawa.
\newblock Expression of chimeric receptor composed of immunoglobulin-derived v
  resions and t-cell receptor-derived c regions.
\newblock \emph{Biochemical and Biophysical Research Communications},
  149\penalty0 (3):\penalty0 960 -- 968, 1987.

\bibitem[Pharmatimes(2018{\natexlab{a}})]{Kymriah}
Pharmatimes.
\newblock Kymriah, 2018{\natexlab{a}}.
\newblock URL
  \url{http://www.pharmatimes.com/news/nhs_england_strikes_deal_with_novartis_on_kymriah_1251397}.
\newblock Accessed = 01/02/2019.

\bibitem[Pharmatimes(2018{\natexlab{b}})]{Yescarta}
Pharmatimes.
\newblock Yescarta, 2018{\natexlab{b}}.
\newblock URL
  \url{http://www.pharmatimes.com/news/gilead_strikes_deal_with_nhs_england_on_yescarta_access_1254812}.
\newblock Accessed = 01/02/2019.

\bibitem[UK(2015)]{CRUK}
Cancer~Research UK.
\newblock Cancer incidence for common cancers, 2015.
\newblock URL
  \url{https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared#ref-}.
\newblock Accessed = 09/02/2019.

\bibitem[Bryan A.~Irving(1991)]{CD3}
Arthur~Weiss Bryan A.~Irving.
\newblock The cytoplasmic domain of the t cell receptor zeta chain is
  sufficient to couple to receptor-associated signal transduction pathways.
\newblock \emph{Cell}, 64\penalty0 (5):\penalty0 891 -- 901, 1991.

\bibitem[FA et~al.(1992)FA, JG, JA, DH, and JP]{survival}
Harding FA, McArthur JG, Gross JA, Raulet DH, and Allison JP.
\newblock Cd28-mediated signalling co-stimulates murine t cells and prevents
  induction of anergy in t-cell clones.
\newblock \emph{Nature}, 356\penalty0 (6370):\penalty0 607 – 609, 1992.

\bibitem[Thompson et~al.(1989)Thompson, Lindsten, Ledbetter, Kunkel, Young,
  Emerson, Leiden, and June]{activation}
C~B Thompson, T~Lindsten, J~A Ledbetter, S~L Kunkel, H~A Young, S~G Emerson,
  J~M Leiden, and C~H June.
\newblock Cd28 activation pathway regulates the production of multiple
  t-cell-derived lymphokines and cytokines.
\newblock \emph{Proc. Natl. Acad. Sci. USA}, 86:\penalty0 1333 -- 1337, 1989.

\bibitem[Long et~al.(2015{\natexlab{a}})Long, Haso, Shern, Wanhainen, Murgai,
  Ingaramo, Smith, Walker, Kohler, Venkateshwara, Kaplan, Patterson, Fry,
  Orentas, and Mackall]{exhaustion}
Adrienne~H. Long, Waleed~M. Haso, Jack~F. Shern, Kelsey~M. Wanhainen, Meera
  Murgai, Maria Ingaramo, Jillian~P. Smith, Alec~J. Walker, M.~Eric Kohler,
  Vikas~R. Venkateshwara, Rosandra~N. Kaplan, George~H. Patterson, Terry~J.
  Fry, Rimas~J. Orentas, and Crystal~L. Mackall.
\newblock 4-1bb costimulation ameliorates t cell exhaustion induced by tonic
  signaling of chimeric antigen receptors.
\newblock \emph{Nat Med}, 21\penalty0 (6):\penalty0 581 -- 590,
  2015{\natexlab{a}}.

\bibitem[van~der Stegen et~al.(2015)van~der Stegen, Hamieh, and
  Sadelain]{CD28-1}
Sjoukje J.~C. van~der Stegen, Mohamad Hamieh, and Michel Sadelain.
\newblock The pharmacology of second-generation chimeric antigen receptors.
\newblock \emph{Nature Reviews Drug Discovery}, 14:\penalty0 499 -- 509, 2015.

\bibitem[Kawalekar et~al.(2016)Kawalekar, O’Connor, Fraietta, Guo,
  McGettigan, Jr., Patel, Guedan, Scholler, Keith, Snyder, Blair, Milone, and
  June]{CD28-2}
Omkar~U. Kawalekar, Roddy~S. O’Connor, Joseph~A. Fraietta, Lili Guo,
  Shannon~E. McGettigan, Avery D.~Posey Jr., Prachi~R. Patel, Sonia Guedan,
  John Scholler, Brian Keith, Nathaniel~W. Snyder, Ian~A. Blair, Michael~C.
  Milone, and Carl~H. June.
\newblock Distinct signaling of coreceptors regulates specific metabolism
  pathways and impacts memory development in car t cells.
\newblock \emph{Immunity}, 44\penalty0 (2):\penalty0 380 -- 390, 2016.

\bibitem[Milone et~al.(2009{\natexlab{a}})Milone, Fish, Carpenito, Carroll,
  Binder, Teachey, Samanta, Lakhal, Gloss, Danet-Desnoyers, Campana, Riley,
  Grupp, and June]{CD28-3}
Michael~C. Milone, Jonathan~D. Fish, Carmine Carpenito, Richard~G. Carroll,
  Gwendolyn~K. Binder, David Teachey, Minu Samanta, Mehdi Lakhal, Brian Gloss,
  Gwenn Danet-Desnoyers, Dario Campana, James~L. Riley, Stephan~A. Grupp, and
  Carl~H. June.
\newblock Chimeric receptors containing cd137 signal transduction domains
  mediate enhanced survival of t cells and increased antileukemic efficacy in
  vivo.
\newblock \emph{Molecular Therapy}, 17\penalty0 (8):\penalty0 1453 -- 1464,
  2009{\natexlab{a}}.

\bibitem[Kalos et~al.(2011)Kalos, Levine, Porter, Katz, Grupp, Bagg, and
  June]{4-1BB}
Michael Kalos, Bruce~L. Levine, David~L. Porter, Sharyn Katz, Stephan~A. Grupp,
  Adam Bagg, and Carl~H. June.
\newblock T cells with chimeric antigen receptors have potent antitumor effects
  and can establish memory in patients with advanced leukemia.
\newblock \emph{Leukemia}, 3\penalty0 (95):\penalty0 95ra73, 2011.

\bibitem[Frauwirth et~al.(2002)Frauwirth, Riley, Harris, Parry, Rathmell, Plas,
  nad Carl H.~June, and Thompson]{CD28-5}
Kenneth~A. Frauwirth, James~L. Riley, Marian~H. Harris, Richard~V. Parry,
  Jeffrey~C. Rathmell, David~R. Plas, Rebecca L.~Elstrom nad Carl H.~June, and
  Craig~B. Thompson.
\newblock The cd28 signaling pathway regulates glucose metabolism.
\newblock \emph{Immunity}, 16:\penalty0 769 -- 777, 2002.

\bibitem[Long et~al.(2015{\natexlab{b}})Long, Haso, Shern, Wanhainen, Murgai,
  Ingaramo, Smith, Walker, Kohler, Venkateshwara, Kaplan, and et.
  al]{CD28-4-1BB-3}
Adrienne~H Long, Waleed~M Haso, Jack~F Shern, Kelsey~M Wanhainen, Meera Murgai,
  Maria Ingaramo, Jillian~P Smith, Alec~J Walker, M~Eric Kohler, Vikas~R
  Venkateshwara, Rosandra~N Kaplan, and George H~Patterson et. al.
\newblock 4-1bb costimulation ameliorates t cell exhaustion induced by tonic
  signaling of chimeric antigen receptors.
\newblock \emph{Nature Medicine}, 21\penalty0 (6):\penalty0 581 -- 590,
  2015{\natexlab{b}}.

\bibitem[Coles et~al.(2012)Coles, Hills, Wang, Burnett, Man, Darley, and
  Tonks]{CD200}
S~J Coles, R~K Hills, E~C~Y Wang, A~K Burnett, S~Man, R~L Darley, and A~Tonks.
\newblock Expression of cd200 on aml blasts directly suppresses memory t-cell
  function.
\newblock \emph{Leukemia}, 26:\penalty0 2142 -- 2158, 2012.

\bibitem[Milone et~al.(2009{\natexlab{b}})Milone, Fish, Carpenito, Carroll,
  Binder, Teachey, Samanta, Lakhal, Gloss, Danet-Desnoyers, Campana, Riley,
  Grupp, and June]{CD137}
Michael~C. Milone, Jonathan~D. Fish, Carmine Carpenito, Richard~G. Carroll,
  Gwendolyn~K. Binder, David Teachey, Minu Samanta, Mehdi Lakhal, Brian Gloss,
  Gwenn Danet-Desnoyers, Dario Campana, James~L. Riley, Stephan~A. Grupp, and
  Carl~H. June.
\newblock Chimeric receptors containing cd137 signal transduction domains
  mediate enhanced survival of t cells and increased antileukemic efficacy in
  vivo.
\newblock \emph{Molecular Therapy}, 17\penalty0 (8):\penalty0 1453 – 1464,
  2009{\natexlab{b}}.

\bibitem[Wang et~al.(2007)Wang, Jensen, Lin, Sui, Chen, Lindgren, Till,
  Raubitschek, Forman, Qian, James, Greenberg, Riddell, and
  Press]{CD28-4-1BB-1}
Jinjuan Wang, Michael Jensen, Yukang Lin, Xingwei Sui, Eric Chen, Catherine~G.
  Lindgren, Brian Till, Andrew Raubitschek, Stephen~J. Forman, Xiaojun Qian,
  Scott James, Philip Greenberg, Stanley Riddell, and Oliver~W. Press.
\newblock Optimizing adoptive polyclonal t cell immunotherapy of lymphomas,
  using a chimeric t cell receptor possessing cd28 and cd137 costimulatory
  domains.
\newblock \emph{Human Gene Therapy}, 18\penalty0 (8):\penalty0 712 -- 725,
  2007.

\bibitem[Zhong et~al.(2010)Zhong, Matsushita, Plotkin, Riviere, and
  Sadelain]{CD28-4-1BB-2}
Xiao-Song Zhong, Maiko Matsushita, Jason Plotkin, Isabelle Riviere, and Michel
  Sadelain.
\newblock Chimeric antigen receptors combining 4-1bb and cd28 signaling domains
  augment pi3kinase/akt/bcl-xl activation and cd8+ t cell–mediated tumor
  eradication.
\newblock \emph{Molecular Therapy}, 18\penalty0 (2):\penalty0 413 -- 420, 2010.

\bibitem[Chmielewski et~al.(2011)Chmielewski, Kopecky, Hombach, and
  Abken]{il12}
Markus Chmielewski, Caroline Kopecky, Andreas~A. Hombach, and Hinrich Abken.
\newblock Il-12 release by engineered t cells expressing chimeric antigen
  receptors can effectively muster an antigen-independent macrophage response
  on tumor cells that have shut down tumor antigen expression.
\newblock \emph{Cancer Research}, 71\penalty0 (17):\penalty0 697 – 706, 2011.

\bibitem[Zhang et~al.(2011)Zhang, Kerkar, Yu, Zheng, Yang, Restifo, Rosenberg,
  and Morgan]{il122}
Ling Zhang, Sid~P Kerkar, Zhiya Yu, Zhili Zheng, Shicheng Yang, Nicholas~P
  Restifo, Steven~A Rosenberg, and Richard~A Morgan.
\newblock Improving adoptive t cell therapy by targeting and controlling il-12
  expression to the tumor environment.
\newblock \emph{Molecular Therapy}, 19\penalty0 (4):\penalty0 751 – 759,
  2011.

\bibitem[Watkins et~al.(2007)Watkins, Egilmez, Suttles, and Stout]{il12macro}
Stephanie~K. Watkins, Nejat~K. Egilmez, Jill Suttles, and Robert~D. Stout.
\newblock Il-12 rapidly alters the functional profile of tumor-associated and
  tumor-infiltrating macrophages in vitro and in vivo.
\newblock \emph{The Journal of Immunology}, 178\penalty0 (3):\penalty0 1357 –
  1362, 2007.

\bibitem[Nishimura et~al.(2000)Nishimura, Yajima, Naiki, Tsunobuchi, Umemura,
  Itano, Matsuguchi, Suzuki, Ohashi, and Yoshikai]{il15cd}
Hitoshi Nishimura, Toshiki Yajima, Yoshikazu Naiki, Hironaka Tsunobuchi,
  Masayuki Umemura, Keiko Itano, Tetsuya Matsuguchi, Misao Suzuki, Pamela~S.
  Ohashi, and Yasunobu Yoshikai.
\newblock Differential roles of interleukin 15 mrna isoforms generated by
  alternative splicing in immune responses in vivo.
\newblock \emph{Journal of Experimental Medicine}, 191\penalty0 (1):\penalty0
  157 – 169, 2000.

\bibitem[Liew and McInnes(2002)]{il18}
F~Y Liew and I~B McInnes.
\newblock Role of interleukin 15 and interleukin 18 in inflammatory response.
\newblock \emph{Annals of the Rheumatic Diseases}, 61:\penalty0 100 – 102,
  2002.

\bibitem[CN et~al.(2003)CN, AD, and M]{NKT}
Baxevanis CN, Gritzapis AD, and Papamichail M.
\newblock In vivo antitumor activity of nkt cells activated by the combination
  of il-12 and il-18.
\newblock \emph{The Journal of Immunology}, 171\penalty0 (6):\penalty0 2953 –
  2959, 2003.

\bibitem[Macatonia et~al.(1995)Macatonia, Hosken, M~Litton, Hsieh, Culpepper,
  Wysocka, Trinchieri, Murphy, and O'Garra]{cd4il12}
S~E Macatonia, N~A Hosken, P~Vieira M~Litton, C~S Hsieh, J~A Culpepper,
  M~Wysocka, G~Trinchieri, K~M Murphy, and A~O'Garra.
\newblock Dendritic cells produce il-12 and direct the development of th1 cells
  from naive cd4+ t cells.
\newblock \emph{The Journal of Immunology}, 154\penalty0 (10):\penalty0 5071
  – 5079, 1995.

\bibitem[Hsieh et~al.(1993)Hsieh, Macatonia, Tripp, Wolf, and
  A~O'Garra]{cd4il122}
CS~Hsieh, SE~Macatonia, CS~Tripp, SF~Wolf, and KM~Murphy A~O'Garra.
\newblock Development of th1 cd4+ t cells through il-12 produced by
  listeria-induced macrophages.
\newblock \emph{Science}, 260\penalty0 (5107):\penalty0 547 – 549, 1993.

\bibitem[Yoo et~al.(2002)Yoo, Cho, Lee, and Sung]{cd4il123}
Jae~Kwang Yoo, Jae~Ho Cho, Seung~Woo Lee, and Young~Chul Sung.
\newblock Il-12 provides proliferation and survival signals to murine cd4+ t
  cells through phosphatidylinositol 3-kinase/akt signaling pathway.
\newblock \emph{The Journal of Immunology}, 169\penalty0 (7):\penalty0 3637 –
  3643, 2002.

\bibitem[Wesa et~al.(2007)Wesa, Kalinski, Kirkwood, Tatsumi, and
  Storkus]{cd4il124}
Amy Wesa, Pawel Kalinski, John~M. Kirkwood, Tomohide Tatsumi, and Walter~J.
  Storkus.
\newblock Polarized type-1 dendritic cells (dc1) producing high levels of il-12
  family members rescue patient th1-type antimelanoma cd4+ t cell responses in
  vitro.
\newblock \emph{Journal of Immunotherapy}, 30\penalty0 (1):\penalty0 75 – 82,
  2007.

\bibitem[J.Smith et~al.(2016)J.Smith, Oertle, Warren, and Prato]{fig1}
Aaron J.Smith, John Oertle, Dan Warren, and Dino Prato.
\newblock Chimeric antigen receptor (car) t cell therapy for malignant cancers:
  Summary and perspective.
\newblock \emph{Journal of Cellular Immunotherapy}, 2\penalty0 (2):\penalty0 59
  -- 68, 2016.

\bibitem[Qin et~al.(2017)Qin, Lai, Zhao, Wei, Weng, Lai, Li, Lin, Wang, Wu,
  Liang, and et. al]{hinge}
Le~Qin, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng
  Li, Simiao Lin, Suna Wang, Qiting Wu, Qiubin Liang, and Yangqiu~Li et. al.
\newblock Incorporation of a hinge domain improves the expansion of chimeric
  antigen receptor t cells.
\newblock \emph{Journal of Hematology \& Oncology}, 10\penalty0 (68), 2017.

\bibitem[Almåsbak et~al.(2015)Almåsbak, Walseng, Kristian, Myhre, Suso,
  Munthe, Andersen, Wang, Kvalheim, Gaudernack, and Kyte]{hinge-2}
H~Almåsbak, E~Walseng, A~Kristian, MR~Myhre, EM~Suso, LA~Munthe, JT~Andersen,
  MY~Wang, G~Kvalheim, G~Gaudernack, and JA~Kyte.
\newblock Inclusion of an igg1-fc spacer abrogates efficacy of cd19 car t cells
  in a xenograft mouse model.
\newblock \emph{Gene Therapy}, 22, 2015.

\bibitem[Hombach et~al.(2010)Hombach, Hombach, and Abken]{hinge-3}
A~Hombach, A~A Hombach, and H~Abken.
\newblock Adoptive immunotherapy with genetically engineered t cells:
  modification of the igg1 fc ‘spacer’ domain in the extracellular moiety
  of chimeric antigen receptors avoids ‘off-target’ activation and
  unintended initiation of an innate immune response.
\newblock \emph{Gene Therapy}, 17, 2010.

\bibitem[Watanabe et~al.(2016)Watanabe, Bajgain, Sukumaran, Ansari, Heslop,
  Rooney, Brenner, Leen, and Vera]{hinge-7}
Norihiro Watanabe, Pradip Bajgain, Sujita Sukumaran, Salma Ansari, Helen~E.
  Heslop, Cliona~M. Rooney, Malcolm~K. Brenner, Ann~M. Leen, and Juan~F. Vera.
\newblock Fine-tuning the car spacer improves t-cell potency.
\newblock \emph{Oncoimmunology}, 5\penalty0 (12), 2016.

\bibitem[Jonnalagadda et~al.(2015)Jonnalagadda, Mardiros, Urak, Wang, Hoffman,
  Bernanke, Chang, Bretzlaff, Starr, Priceman, Ostberg, Forman, and
  Brown]{hinge-4}
Mahesh Jonnalagadda, Armen Mardiros, Ryan Urak, Xiuli Wang, Lauren~J Hoffman,
  Alyssa Bernanke, Wen-Chung Chang, William Bretzlaff, Renate Starr, Saul
  Priceman, Julie~R Ostberg, Stephen~J Forman, and Christine~E Brown.
\newblock Chimeric antigen receptors with mutated igg4 fc spacer avoid fc
  receptor binding and improve t cell persistence and antitumor efficacy.
\newblock \emph{Molecular Therapy}, 23\penalty0 (4), 2015.

\bibitem[CE et~al.(2018)CE, B, R, X, WC, L, B, A, A, JF, JR, M, B, ME, and
  SJ]{hinge-5}
Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, Chang B, Sarkissian A,
  Brito A, Sanchez JF, Ostberg JR, D'Apuzzo M, Badie B, Barish ME, and Forman
  SJ.
\newblock Optimization of il13ra2-targeted chimeric antigen receptor t cells
  for improved anti-tumor efficacy against glioblastoma.
\newblock \emph{Molecular Therapy}, 26\penalty0 (1), 2018.

\bibitem[Guest et~al.(2005)Guest, Hawkins, Kirillova, Cheadle, Arnold, O'Neill,
  Irlam, Chester, Kemshead, Shaw, Embleton, Stern, and Gilham]{hinge-6}
Ryan Guest, Robert Hawkins, Natalia Kirillova, Eleanor Cheadle, Jennifer
  Arnold, Allison O'Neill, Joely Irlam, Kerry Chester, John Kemshead, David
  Shaw, M~Embleton, Peter Stern, and David Gilham.
\newblock The role of extracellular spacer regions in the optimal design of
  chimeric immune receptors: Evaluation of four different scfvs and antigens.
\newblock \emph{Journal of Immunotherapy}, 28\penalty0 (3), 2005.

\bibitem[Davila et~al.(2014)Davila, Riviere, Wang, Bartido, Park, Curran,
  Chung, Stefanski, Borquez-Ojeda, Olszewska, Qu, Wasielewska, He, Fink,
  Shinglot, Youssif, Satter, Wang, Hosey, Quintanilla, Halton, Bernal,
  Bouhassira, Arcila, Gonen, Roboz, Maslak, Douer, Frattini, Giralt, Sadelain,
  and Brentjens]{ALL}
Marco~L. Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park,
  Kevin Curran, Stephen~S. Chung, Jolanta Stefanski, Oriana Borquez-Ojeda,
  Malgorzata Olszewska, Jinrong Qu, Teresa Wasielewska, Qing He, Mitsu Fink,
  Himaly Shinglot, Maher Youssif, Mark Satter, Yongzeng Wang, James Hosey,
  Hilda Quintanilla, Elizabeth Halton, Yvette Bernal, Diana C.~G. Bouhassira,
  Maria~E. Arcila, Mithat Gonen, Gail~J. Roboz, Peter Maslak, Dan Douer,
  Mark~G. Frattini, Sergio Giralt, Michel Sadelain, and Renier Brentjens.
\newblock Efficacy and toxicity management of 19-28z car t cell therapy in b
  cell acute lymphoblastic leukemia.
\newblock \emph{Science Translational Medicine}, 6\penalty0 (224):\penalty0 224
  – 225, 2014.

\bibitem[Maude et~al.(2014{\natexlab{a}})Maude, Frey, Shaw, Aplenc, Barrett,
  Bunin, Chew, Gonzalez, Zheng, Lacey, Mahnke, Melenhorst, Rheingold, Shen,
  Teachey, Levine, June, Porter, and Grupp]{ALL2}
Shannon~L. Maude, Noelle Frey, Pamela~A. Shaw, Richard Aplenc, David~M.
  Barrett, Nancy~J. Bunin, Anne Chew, Vanessa~E. Gonzalez, Zhaohui Zheng,
  Simon~F. Lacey, Yolanda~D. Mahnke, Jan~J. Melenhorst, Susan~R. Rheingold,
  Angela Shen, David~T. Teachey, Bruce~L. Levine, Carl~H. June, David~L.
  Porter, and Stephan~A. Grupp.
\newblock Chimeric antigen receptor t cells for sustained remissions in
  leukemia.
\newblock \emph{The New England Journal of Medicine}, 371\penalty0
  (16):\penalty0 1507 -- 1517, 2014{\natexlab{a}}.

\bibitem[Maude et~al.(2015)Maude, Teachey, Porter, and Grupp]{acute}
Shannon~L. Maude, David~T. Teachey, David~L. Porter, and Stephan~A. Grupp.
\newblock Cd19-targeted chimeric antigen receptor t-cell therapy for acute
  lymphoblastic leukemia.
\newblock \emph{Blood}, 125\penalty0 (26):\penalty0 4017 -- 4023, 2015.

\bibitem[DW et~al.(2015)DW, JN, M, YK, C, SA, TJ, R, M, NN, SM, D, N, C, H, L,
  SA, AS, and CL]{acute2}
Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA,
  Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia
  N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, and Mackall CL.
\newblock T cells expressing cd19 chimeric antigen receptors for acute
  lymphoblastic leukaemia in children and young adults: a phase 1
  dose-escalation trial.
\newblock \emph{The Lancet}, 385\penalty0 (9967):\penalty0 517 -- 528, 2015.

\bibitem[Porter1 et~al.(2015)Porter1, Hwang, Frey, Lacey, Shaw, Loren, Bagg,
  Marcucci, Shen, Gonzalez, Ambrose, Grupp, Chew, Zheng, Milone, Levine,
  Melenhorst, and June]{chronic}
David~L. Porter1, Wei-Ting Hwang, Noelle~V. Frey, Simon~F. Lacey, Pamela~A.
  Shaw, Alison~W. Loren, Adam Bagg, Katherine~T. Marcucci, Angela Shen, Vanessa
  Gonzalez, David Ambrose, Stephan~A. Grupp, Anne Chew, Zhaohui Zheng,
  Michael~C. Milone, Bruce~L. Levine, Jan~J. Melenhorst, and Carl~H. June.
\newblock Chimeric antigen receptor t cells persist and induce sustained
  remissions in relapsed refractory chronic lymphocytic leukemia.
\newblock \emph{Science Translational Medicine}, 7\penalty0 (303):\penalty0
  303ra139, 2015.

\bibitem[Turtle et~al.(2016)Turtle, Hanafi, Berger, Hudecek, Pender, Robinson,
  Hawkins, Chaney, Cherian, Chen, Soma, Wood, Li, Heimfeld, Riddell, and
  Maloney]{lymphoma}
Cameron~J. Turtle, Laïla-Aïcha Hanafi, Carolina Berger, Michael Hudecek,
  Barbara Pender, Emily Robinson, Reed Hawkins, Colette Chaney, Sindhu Cherian,
  Xueyan Chen, Lorinda Soma, Brent Wood, Daniel Li, Shelly Heimfeld, Stanley~R.
  Riddell, and David~G. Maloney.
\newblock Immunotherapy of non-hodgkin’s lymphoma with a defined ratio of
  cd8+ and cd4+ cd19-specific chimeric antigen receptor–modified t cells.
\newblock \emph{Science Translational Medicine}, 8\penalty0 (355):\penalty0
  355ra116, 2016.

\bibitem[Grupp et~al.(2013{\natexlab{a}})Grupp, Kalos, Barrett, Aplenc, Porter,
  Rheingold, Teachey, Chew, Hauck, Wright, Milone, Levine, and June]{cyto-1}
Stephan~A. Grupp, Michael Kalos, David Barrett, Richard Aplenc, David~L.
  Porter, Susan~R. Rheingold, David~T. Teachey, Anne Chew, Bernd Hauck,
  J.~Fraser Wright, Michael~C. Milone, Bruce~L. Levine, and Carl~H. June.
\newblock Chimeric antigen receptor–modified t cells for acute lymphoid
  leukemia.
\newblock \emph{New England Journal of Medicine}, 368\penalty0 (16):\penalty0
  1509 -- 1518, 2013{\natexlab{a}}.

\bibitem[Xiao-JunXu and Yong-MinTang(2014)]{cyto-9}
Xiao-JunXu and Yong-MinTang.
\newblock Cytokine release syndrome in cancer immunotherapy with chimeric
  antigen receptor engineered t cells.
\newblock \emph{Cancer Letters}, 343\penalty0 (2):\penalty0 172 -- 178, 2014.

\bibitem[Brentjens et~al.(2013{\natexlab{a}})Brentjens, Davila, Riviere†,
  Park, Wang, Cowe, Bartido, Stefanski, Taylor, Olszewska, Borquez-Ojeda, Qu,
  Wasielewska, He, Bernal, Rijo, Hedvat, Kobos, Curran, Steinherz, Jurcic,
  Rosenblat, Maslak, Frattini, and Sadelain]{cyto-2}
Renier Brentjens, Marco~L Davila, Isabelle Riviere†, Jae Park, Xiuyan Wang,
  Lindsay~G Cowe, Shirley Bartido, Jolanta Stefanski, Clare Taylor, Malgorzata
  Olszewska, Oriana Borquez-Ojeda, Jinrong Qu, Teresa Wasielewska, Qing He,
  Yvette Bernal, Ivelise~V Rijo, Cyrus Hedvat, Rachel Kobos, Kevin Curran,
  Peter Steinherz, Joseph Jurcic, Todd Rosenblat, Peter Maslak, Mark Frattini,
  and Michel Sadelain.
\newblock Cd19-targeted t cells rapidly induce molecular remissions in adults
  with chemotherapy-refractory acute lymphoblastic leukemia.
\newblock \emph{Science Translational Medicine}, 5\penalty0 (177):\penalty0
  177ra38, 2013{\natexlab{a}}.

\bibitem[Park et~al.(2018)Park, Rivière, Gonen, Wang, Sénéchal, Curran,
  Sauter, Wang, Santomasso, Mead, Roshal, and Maslak]{cyto-3}
Jae~H. Park, Isabelle Rivière, Mithat Gonen, Xiuyan Wang, Brigitte Sénéchal,
  Kevin~J. Curran, Craig Sauter, Yongzeng Wang, Bianca Santomasso, Elena Mead,
  Mikhail Roshal, and Peter Maslak.
\newblock Long-term follow-up of cd19 car therapy in acute lymphoblastic
  leukemia.
\newblock \emph{New England Journal of Medicine}, 378\penalty0 (5):\penalty0
  449 -- 459, 2018.

\bibitem[Schuster et~al.(2017)Schuster, Svoboda, Chong, Nasta, Mato, Özlem
  Anak, Brogdon, Pruteanu-Malinici, Bhoj, Landsburg, Wasik, Levine, Lacey,
  Melenhorst, Porter, and June]{cyto-4}
Stephen~J. Schuster, Jakub Svoboda, Elise~A. Chong, Sunita~D. Nasta, Anthony~R.
  Mato, Özlem Anak, Jennifer~L. Brogdon, Iulian Pruteanu-Malinici, Vijay Bhoj,
  Daniel Landsburg, Mariusz Wasik, Bruce~L. Levine, Simon~F. Lacey, Jan~J.
  Melenhorst, David~L. Porter, and Carl~H. June.
\newblock Chimeric antigen receptor t cells in refractory b-cell lymphomas.
\newblock \emph{New England Journal of Medicine}, 377\penalty0 (26):\penalty0
  2545 -- 2554, 2017.

\bibitem[Lee et~al.(2015)Lee, Kochenderfer, Stetler-Stevenson, Cui,
  Cindy~Delbrook, Fry, Orentas, Sabatino, Shah, Steinberg, Stroncek,
  Nick~Tschernia, Zhang, Zhang, Rosenberg, Wayne, and Mackall]{cyto-5}
Daniel~W Lee, James~N Kochenderfer, Maryalice Stetler-Stevenson, Yongzhi~K Cui,
  RN~Steven A~Feldman Cindy~Delbrook, Terry~J Fry, Rimas Orentas, Marianna
  Sabatino, Nirali~N Shah, Seth~M Steinberg, Dave Stroncek, BS~Constance~Yuan
  Nick~Tschernia, Hua Zhang, Ling Zhang, Prof Steven~A Rosenberg, Prof Alan~S
  Wayne, and Dr~Crystal~L Mackall.
\newblock Tisagenlecleucel in children and young adults with b-cell
  lymphoblastic leukemia.
\newblock \emph{The Lancet}, 385\penalty0 (9967):\penalty0 517 -- 528, 2015.

\bibitem[Ali et~al.(2016)Ali, Shi, Maric, Wang, Stroncek, Rose, Brudno,
  Stetler-Stevenson, Feldman, Hansen, Fellowes, Hakim, Gress, and
  Kochenderfer]{cyto-6}
Syed~Abbas Ali, Victoria Shi, Irina Maric, Michael Wang, David~F. Stroncek,
  Jeremy~J. Rose, Jennifer~N. Brudno, Maryalice Stetler-Stevenson, Steven~A.
  Feldman, Brenna~G. Hansen, Vicki~S. Fellowes, Frances~T. Hakim, Ronald~E.
  Gress, and James~N. Kochenderfer.
\newblock T cells expressing an anti–b-cell maturation antigen chimeric
  antigen receptor cause remissions of multiple myeloma.
\newblock \emph{Blood}, 128\penalty0 (13):\penalty0 1688 -- 1700, 2016.

\bibitem[Maude et~al.(2018)Maude, Laetsch, Buechner, Rives, Boyer, Bittencourt,
  Bader, Verneris, Stefanski, Myers, Qayed, and et~al]{cyto-7}
Shannon~L. Maude, Theodore~W. Laetsch, Jochen Buechner, Susana Rives, Michael
  Boyer, Henrique Bittencourt, Peter Bader, Michael~R. Verneris, Heather~E.
  Stefanski, Gary~D. Myers, Muna Qayed, and Barbara De~Moerloose et~al.
\newblock Tisagenlecleucel in children and young adults with b-cell
  lymphoblastic leukemia.
\newblock \emph{New England Journal of Medicine}, 378\penalty0 (5):\penalty0
  439 -- 448, 2018.

\bibitem[Maude et~al.(2014{\natexlab{b}})Maude, Teachey, Porter, and
  Grupp]{cyto-8}
Shannon~L. Maude, David~T. Teachey, David~L. Porter, and Stephan~A. Grupp.
\newblock Cd19-targeted chimeric antigen receptor t-cell therapy for acute
  lymphoblastic leukemia.
\newblock \emph{Blood}, 125\penalty0 (26):\penalty0 4017 -- 4023,
  2014{\natexlab{b}}.

\bibitem[Couper et~al.(2008)Couper, Blount, and Riley]{il10}
Kevin~N. Couper, Daniel~G. Blount, and Eleanor~M. Riley.
\newblock Il-10: The master regulator of immunity to infection.
\newblock \emph{The Journal of Immunology}, 180\penalty0 (9):\penalty0 5771 --
  5777, 2008.

\bibitem[ichiro Fujii et~al.(2001)ichiro Fujii, Shimizu, Shimizu, and
  Lotze]{il10-2}
Shin ichiro Fujii, Kanako Shimizu, Takashi Shimizu, and Michael~T. Lotze.
\newblock Interleukin-10 promotes the maintenance of antitumor cd8+ t-cell
  effector function in situ.
\newblock \emph{Blood}, 98:\penalty0 2143 -- 2151, 2001.

\bibitem[Bonifant et~al.(2016)Bonifant, Jackson, Brentjens, and
  Curran]{cyto-10}
Challice~L Bonifant, Hollie~J Jackson, Renier~J Brentjens, and Kevin~J Curran.
\newblock Toxicity and management in car t-cell therapy.
\newblock \emph{Molecular Therapy Oncolytics}, 3\penalty0 (16011), 2016.

\bibitem[Gust et~al.(2017)Gust, Hay, Hanafi, Li, Myerson, Gonzalez-Cuyar,
  Yeung, Liles, Wurfel, Lopez, Chen, and et~al]{cyto-11}
Juliane Gust, Kevin~A. Hay, Laïla-Aïcha Hanafi, Daniel Li, David Myerson,
  Luis~F. Gonzalez-Cuyar, Cecilia Yeung, W.~Conrad Liles, Mark Wurfel, Jose~A.
  Lopez, Junmei Chen, and Dominic~Chung et~al.
\newblock Endothelial activation and blood–brain barrier disruption in
  neurotoxicity after adoptive immunotherapy with cd19 car-t cells.
\newblock \emph{Cancer Discovery}, 2017.

\bibitem[Larochelle et~al.(2011)Larochelle, Alvarez, and Prat]{BBB-1}
Catherine Larochelle, Jorge~Ivan Alvarez, and Alexandre Prat.
\newblock How do immune cells overcome the blood–brain barrier in multiple
  sclerosis?
\newblock \emph{FEBS Letter}, 585\penalty0 (23):\penalty0 3770 -- 3780, 2011.

\bibitem[Descamps et~al.(1997)Descamps, Cecchelli, and Torpier]{BBB-4}
Laurence Descamps, Roméo Cecchelli, and Gérard Torpier.
\newblock Effects of tumor necrosis factor on receptor-mediated endocytosis and
  barrier function of bovine brain capillary endothelial cell monolayers.
\newblock \emph{Journal of Neuroimmunology}, 74\penalty0 (1-2):\penalty0 173 --
  184, 1997.

\bibitem[G.Mayhan(2002)]{BBB-5}
William G.Mayhan.
\newblock Cellular mechanisms by which tumor necrosis factor-α produces
  disruption of the blood–brain barrier.
\newblock \emph{Brain Research}, 927\penalty0 (2):\penalty0 144 -- 152, 2002.

\bibitem[Lv et~al.(2010)Lv, Song, Zhou, Li, Cui, Wang, and Liu]{BBB-2}
Sa~Lv, Hong‐Li Song, Ying Zhou, Li‐Xin Li, Wei Cui, Wen Wang, and Pei Liu.
\newblock Tumour necrosis factor-alpha affects blood–brain barrier
  permeability and tight junction-associated occludin in acute liver failure.
\newblock \emph{Liver International}, 30\penalty0 (8):\penalty0 1198 -- 1210,
  2010.

\bibitem[Alvareza et~al.(2011)Alvareza, Cayrola, and Prat]{BBB-3}
Jorge~Ivan Alvareza, Romain Cayrola, and Alexandre Prat.
\newblock Disruption of central nervous system barriers in multiple sclerosis.
\newblock \emph{Biochimica et Biophysica Acta (BBA) - Molecular Basis of
  Disease}, 1812\penalty0 (2):\penalty0 252 -- 264, 2011.

\bibitem[Dai et~al.(2015)Dai, Zhang, Li, Han, Guo, Zhang, Wang, Wang, Shi,
  Zhang, Chen, Feng, Wang, Zhu, Fu, Li, and Han]{allo-3}
Hanren Dai, Wenying Zhang, Xiaolei Li, Qingwang Han, Yelei Guo, Yajing Zhang,
  Yao Wang, Chunmeng Wang, Fengxia Shi, Yan Zhang, Meixia Chen, Kaichao Feng,
  Quanshun Wang, Hongli Zhu, Xiaobing Fu, Suxia Li, and Weidong Han.
\newblock Tolerance and efficacy of autologous or donor-derived t cells
  expressing cd19 chimeric antigen receptors in adult b-all with extramedullary
  leukemia.
\newblock \emph{Oncoimmunology}, 4\penalty0 (11), 2015.

\bibitem[Maus et~al.(2013)Maus, Haas, Beatty, Albelda, Levine, Liu, Zhao,
  Kalos, and June]{allo-4}
Marcela~V. Maus, Andrew~R. Haas, Gregory~L. Beatty, Steven~M. Albelda, Bruce~L.
  Levine, Xiaojun Liu, Yangbing Zhao, Michael Kalos, and Carl~H. June.
\newblock T cells expressing chimeric antigen receptors can cause anaphylaxis
  in humans.
\newblock \emph{Cancer Immunology Research}, 1\penalty0 (1), 2013.

\bibitem[Ghosh et~al.(2017)Ghosh, Smith1, James, Davila2, Velardi,
  Argyropoulos, Gunset, Perna, Kreines, Levy, Lieberman, and et~al]{allo-5}
Arnab Ghosh, Melody Smith1, Scott~E. James, Marco~L. Davila2, Enrico Velardi,
  Kimon~V. Argyropoulos, Gertrude Gunset, Fabiana Perna, Fabiana~M. Kreines,
  Emily~R. Levy, Sophie Lieberman, and Hilary~Jay et~al.
\newblock Donor cd19-car t cells exert potent graft-versus-lymphoma activity
  with diminished graft-versus-host activity.
\newblock \emph{Nature Medicine}, 23\penalty0 (2):\penalty0 242 -- 249, 2017.

\bibitem[Zhao et~al.(2015)Zhao, Condomines, van~der Stegen, Perna, Kloss,
  Gunset, Plotkin, and Sadelain]{CD28-4}
Zeguo Zhao, Maud Condomines, Sjoukje~J.C. van~der Stegen, Fabiana Perna,
  Christopher~C. Kloss, Gertrude Gunset, Jason Plotkin, and Michel Sadelain.
\newblock Structural design of engineered costimulation determines tumor
  rejection kinetics and persistence of car t cells.
\newblock \emph{Cancer Cell}, 28\penalty0 (4):\penalty0 415 -- 428, 2015.

\bibitem[Grupp et~al.(2013{\natexlab{b}})Grupp, Kalos, Barrett, Aplenc, Porter,
  Rheingold, Teachey, Chew, Hauck, Wright, Milone, Levine, and June]{aplasia}
Stephan~A. Grupp, Michael Kalos, David Barrett, Richard Aplenc, David~L.
  Porter, Susan~R. Rheingold, David~T. Teachey, Anne Chew, Bernd Hauck,
  J.~Fraser Wright, Michael~C. Milone, Bruce~L. Levine, and Carl~H. June.
\newblock Chimeric antigen receptor–modified t cells for acute lymphoid
  leukemia.
\newblock \emph{The New England Journal of Medicine}, 368\penalty0
  (16):\penalty0 1509 -- 1518, 2013{\natexlab{b}}.

\bibitem[Kochenderfer et~al.(2012)Kochenderfer, Dudley, Feldman, Wilson,
  Spaner, Maric, Stetler-Stevenson, Phan, Hughes, Sherry, Yang, and
  et.al]{aplasia-3}
James~N. Kochenderfer, Mark~E. Dudley, Steven~A. Feldman, Wyndham~H. Wilson,
  David~E. Spaner, Irina Maric, Maryalice Stetler-Stevenson, Giao~Q. Phan,
  Marybeth~S. Hughes, Richard~M. Sherry, James~C. Yang, and Udai S.~Kammula
  et.al.
\newblock B-cell depletion and remissions of malignancy along with
  cytokine-associated toxicity in a clinical trial of anti-cd19
  chimeric-antigen-receptor–transduced t cells.
\newblock \emph{Blood}, 119\penalty0 (12), 2012.

\bibitem[Brentjens et~al.(2013{\natexlab{b}})Brentjens, Davila, Riviere, Park,
  Wang, Cowell, Bartido, Stefanski, Taylor, Olszewska, Borquez-Ojeda, and
  et.al]{aplasia-2}
Renier Brentjens, Marco~L Davila, Isabelle Riviere, Jae Park, Xiuyan Wang,
  Lindsay~G Cowell, Shirley Bartido, Jolanta Stefanski, Clare Taylor,
  Malgorzata Olszewska, Oriana Borquez-Ojeda, and Jinrong~Qu et.al.
\newblock Cd19-targeted t cells rapidly induce molecular remissions in adults
  with chemotherapy-refractory acute lymphoblastic leukemia.
\newblock \emph{Science Translational Medicine}, 5\penalty0 (177),
  2013{\natexlab{b}}.

\bibitem[Maus et~al.(2012)Maus, Grupp, Porter, and June]{aplasia-4}
Marcela~V. Maus, Stephan~A. Grupp, David~L. Porter, and Carl~H. June.
\newblock Antibody-modified t cells: Cars take the front seat for hematologic
  malignancies.
\newblock \emph{Blood}, 123\penalty0 (17):\penalty0 2625 -- 2635, 2012.

\bibitem[Tasian and Gardner(2015)]{aplasia-5}
Sarah~K. Tasian and Rebecca~A. Gardner.
\newblock Cd19-redirected chimeric antigen receptor-modified t cells: a
  promising immunotherapy for children and adults with b-cell acute
  lymphoblastic leukemia (all).
\newblock \emph{Therapeutic Advances in Hematology}, 6\penalty0 (5):\penalty0
  228 -- 241, 2015.

\bibitem[Knochelmann et~al.(2018)Knochelmann, Smith, Dwyer, Wyatt, Mehrotra,
  and Paulos]{blueprints}
Hannah~M. Knochelmann, Aubrey~S. Smith, Connor~J. Dwyer, Megan~M. Wyatt,
  Shikhar Mehrotra, and Chrystal~M. Paulos.
\newblock Car t cells in solid tumors: Blueprints for building effective
  therapies.
\newblock \emph{Frontiers in Immunology}, 9\penalty0 (1740), 2018.

\bibitem[D’Aloia et~al.(2018)D’Aloia, Zizzari, Sacchetti, Pierelli, and
  Alimandi]{traffick-2}
Maria~Michela D’Aloia, Ilaria~Grazia Zizzari, Benedetto Sacchetti, Luca
  Pierelli, and Maurizio Alimandi.
\newblock Car-t cells: the long and winding road to solid tumors.
\newblock \emph{Cell Death and Disease}, 9\penalty0 (3):\penalty0 282, 2018.

\bibitem[Newick et~al.(2016)Newick, Moon, and Albelda]{traffick-1}
Kheng Newick, Edmund Moon, and Steven~M Albelda.
\newblock Chimeric antigen receptor t-cell therapy for solid tumors.
\newblock \emph{Molecular Therapy - Oncolytics}, 3:\penalty0 16006, 2016.

\bibitem[Samaha et~al.(2018)Samaha, Pignata, Fousek, ren, lam, Stossi,
  Dubrulle, Salsman, Krishnan, Hong, l.~Baker, and et.al]{homing}
Heba Samaha, Antonella Pignata, Kristen Fousek, Jun ren, Fong~W. lam, Fabio
  Stossi, Julien Dubrulle, Vita~S. Salsman, Shanmugarajan Krishnan, Sung-Ha
  Hong, Matthew l.~Baker, and Ankita~Shree et.al.
\newblock A homing system targets therapeutic t cells to brain cancer.
\newblock \emph{Nature}, 561:\penalty0 331 -- 337, 2018.

\bibitem[Washington et~al.(1994)Washington, Burton, III, Newman, Dragovic, and
  Dore‐Duffy]{MS}
Ruth Washington, Jeffrey Burton, Robert F.~Todd III, Walter Newman, Ljubisa
  Dragovic, and Dr.~Paula Dore‐Duffy.
\newblock Expression of immunologically relevant endothelial cell activation
  antigens on isolated central neurvous system microvessels from patients with
  multiple sclerosis.
\newblock \emph{Annals of Neurology}, 31:\penalty0 89 -- 97, 1994.

\bibitem[Craddock et~al.(2010)Craddock, Lu, Bear, Pule, Brenner, Rooney, and
  Foster]{CCR2-2}
John~A Craddock, An~Lu, Adham Bear, Martin Pule, Malcolm~K Brenner, Cliona~M
  Rooney, and Aaron~E Foster.
\newblock Enhanced tumor trafficking of gd2 chimeric antigen receptor t cells
  by expression of the chemokine receptor ccr2b.
\newblock \emph{Journal of Immunotherapy}, 33\penalty0 (8):\penalty0 780 --
  788, 2010.

\bibitem[A et~al.(2009)A, B, CM, L, A, AE, HE, MK, G, and B]{CCR}
Di~Stasi A, De~Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop
  HE, Brenner MK, Dotti G, and Savoldo B.
\newblock T lymphocytes coexpressing ccr4 and a chimeric antigen receptor
  targeting cd30 have improved homing and antitumor activity in a hodgkin tumor
  model.
\newblock \emph{Blood}, 113\penalty0 (25):\penalty0 6392 -- 6402, 2009.

\bibitem[W et~al.(2010)W, Y, BA, C, Y, M, M, Y, WW, G, and P]{CCR-2}
Peng W, Ye~Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y,
  Overwijk WW, Lizée G, and Hwu P.
\newblock Transduction of tumor-specific t cells with cxcr2 chemokine receptor
  improves migration to tumor and antitumor immune responses.
\newblock \emph{Clinical Cancer Research}, 16\penalty0 (22):\penalty0 5458 --
  5468, 2010.

\bibitem[Moon et~al.(2011)Moon, Carpenito, Sun, Wang, Kapoor, Predina, Daniel
  J.~Powell, Riley, June, and Albelda]{CCR2}
Edmund~K. Moon, Carmine Carpenito, Jing Sun, Liang-Chuan~S Wang, Veena Kapoor,
  Jarrod Predina, Jr. Daniel J.~Powell, James~L. Riley, Carl~H. June, and
  Steven~M. Albelda.
\newblock Expression of a functional ccr2 receptor enhances tumor localization
  and tumor eradication by retargeted human t cells expressing a mesothelin -
  specific chimeric antibody receptor.
\newblock \emph{Clinical Cancer Research}, 17\penalty0 (14):\penalty0 4719 --
  4730, 2011.

\bibitem[Caruana et~al.(2015)Caruana, Savoldo, Hoyos, Weber, Liu, Kim, Ittmann,
  Marchetti, and Dotti]{heparanase}
Ignazio Caruana, Barbara Savoldo, Valentina Hoyos, Gerrit Weber, Hao Liu,
  Eugene~S. Kim, Michael~M. Ittmann, Dario Marchetti, and Gianpietro Dotti.
\newblock Heparanase promotes tumor infiltration and antitumor activity of
  car-redirected t lymphocytes.
\newblock \emph{Nature Medicine}, 21\penalty0 (5):\penalty0 524 -- 529, 2015.

\bibitem[Jezierska and Motyl(2009)]{MMP2}
Agnieszka Jezierska and Tomasz Motyl.
\newblock Matrix metalloproteinase-2 involvement in breast cancer progression:
  a mini-review.
\newblock \emph{Medical Science Monitor}, 15\penalty0 (2):\penalty0 32 -- 40,
  2009.

\bibitem[Dong et~al.(2011)Dong, Li, Zhang, Yang, Guo, Li, and Liu]{MMP2-2}
Wei Dong, Hong Li, Yan Zhang, Heng Yang, Min Guo, Li~Li, and Tongjun Liu.
\newblock Matrix metalloproteinase 2 promotes cell growth and invasion in
  colorectal cancer.
\newblock \emph{Acta Biochimica et Biophysica Sinica}, 43\penalty0
  (11):\penalty0 840 -- 848, 2011.

\bibitem[Mehner et~al.(2014)Mehner, Hockla, Miller, Ran, Radisky, and
  Radisky]{MMP9}
Christine Mehner, Alexandra Hockla, Erin Miller, Sophia Ran, Derek~C. Radisky,
  and Evette~S. Radisky.
\newblock Tumor cell-produced matrix metalloproteinase 9 (mmp-9) drives
  malignant progression and metastasis of basal-like triple negative breast
  cancer.
\newblock \emph{Oncotarget}, 5\penalty0 (9):\penalty0 2736 -- 2749, 2014.

\bibitem[Gialeli et~al.(2011)Gialeli, Theocharis, and Karamanos]{MMPs}
Chrisostomi Gialeli, Achilleas~D. Theocharis, and Nikos~K. Karamanos.
\newblock Roles of matrix metalloproteinases in cancer progression and their
  pharmacological targeting.
\newblock \emph{FEBS Journal}, 287\penalty0 (1):\penalty0 16 -- 27, 2011.

\bibitem[Korpi et~al.(2008)Korpi, Kervinen, Mäklin, Väänänen, Lahtinen,
  Läärä, Ristimäki, Thomas, Ylipalosaari, Åström, Lopez-Otin, Sorsa,
  Kantola, Pirilä, and Salo]{MMP8}
J~T Korpi, V~Kervinen, H~Mäklin, A~Väänänen, M~Lahtinen, E~Läärä,
  A~Ristimäki, G~Thomas, M~Ylipalosaari, P~Åström, C~Lopez-Otin, T~Sorsa,
  S~Kantola, E~Pirilä, and T~Salo.
\newblock Collagenase-2 (matrix metalloproteinase-8) plays a protective role in
  tongue cancer.
\newblock \emph{British Journal of Cancer}, 98\penalty0 (4):\penalty0 1766 --
  775, 2008.

\bibitem[Decock et~al.(2008)Decock, Hendrickx, Vanleeuw, Belle, Huffel,
  Christiaens, Ye, and Paridaens]{MMP8-2}
Julie Decock, Wouter Hendrickx, Ulla Vanleeuw, Vanya~Van Belle, Sabine~Van
  Huffel, Marie-Rose Christiaens, Shu Ye, and Robert Paridaens.
\newblock Plasma mmp1 and mmp8 expression in breast cancer: Protective role of
  mmp8 against lymph node metastasis.
\newblock \emph{BioMed Central Cancer}, 8\penalty0 (77), 2008.

\bibitem[Decock et~al.(2015)Decock, Hendrickx, Thirkettle,
  Gutiérrez-Fernández, Robinson, and Edwards]{MMP8-3}
Julie Decock, Wouter Hendrickx, Sally Thirkettle, Ana Gutiérrez-Fernández,
  Stephen~D Robinson, and Dylan~R Edwards.
\newblock Pleiotropic functions of the tumor- and metastasis-suppressing matrix
  metalloproteinase-8 in mammary cancer in mmtv-pymt transgenic mice.
\newblock \emph{Breast Cancer Research}, 17\penalty0 (1):\penalty0 38, 2015.

\bibitem[Gutiérrez-Fernández et~al.(2008)Gutiérrez-Fernández, Fueyo,
  Folgueras, Garabaya, Pennington, Pilgrim, Edwards, Holliday, Jones, Span,
  Sweep, Puente, and López-Otín]{MMP8-4}
Ana Gutiérrez-Fernández, Antonio Fueyo, Alicia~R. Folgueras, Cecilia
  Garabaya, Caroline~J. Pennington, Simon Pilgrim, Dylan~R. Edwards, Deborah~L.
  Holliday, J.~Louise Jones, Paul~N. Span, Fred~C.G.J. Sweep, Xose~S. Puente,
  and Carlos López-Otín.
\newblock Matrix metalloproteinase-8 functions as a metastasis suppressor
  through modulation of tumor cell adhesion and invasion.
\newblock \emph{Cancer Research}, 68\penalty0 (8), 2008.

\bibitem[Stadlmanna et~al.(2003)Stadlmanna, Pollheimerb, Mosera, Raggic,
  Ambergerd, Margreiterd, Offnere, Mikuza, Dirnhoferc, and Moch]{MMP8-5}
S.~Stadlmanna, J.~Pollheimerb, P.L. Mosera, A.~Raggic, A.~Ambergerd,
  R.~Margreiterd, F.A. Offnere, G.~Mikuza, S.~Dirnhoferc, and H.~Moch.
\newblock Cytokine-regulated expression of collagenase-2 (mmp-8) is involved in
  the progression of ovarian cancer.
\newblock \emph{European Journal of Cancer}, 39\penalty0 (17):\penalty0 2499 --
  2505, 2003.

\bibitem[Qin et~al.(2016)Qin, Luo, Chen, Dang, Chen, Li, Zeng, Lu, and
  Yang]{MMP8-6}
Guihui Qin, Min Luo, Junze Chen, Yiwu Dang, Gang Chen, Li~Li, Jing Zeng, Yi~Lu,
  and Jie Yang.
\newblock Reciprocal activation between mmp-8 and tgf-β1 stimulates emt and
  malignant progression of hepatocellular carcinoma.
\newblock \emph{Cancer Letters}, 374\penalty0 (1):\penalty0 85 -- 95, 2016.

\bibitem[Soria-Valles et~al.(2014)Soria-Valles, Gutiérrez-Fernández, Guiu,
  Mari, Fueyo, Gomis, and López-Otín]{MMP8-8}
C~Soria-Valles, A~Gutiérrez-Fernández, M~Guiu, B~Mari, A~Fueyo, R~R Gomis,
  and C~López-Otín.
\newblock The anti-metastatic activity of collagenase-2 in breast cancer cells
  is mediated by a signaling pathway involving decorin and mir-21.
\newblock \emph{Oncogene}, 33:\penalty0 3054 -- 3063, 2014.

\bibitem[C et~al.(2004)C, AA, U, H, and JA]{MMP8-7}
Kuropkat C, Duenne AA, Herz U, Renz H, and Werner JA.
\newblock Significant correlation of matrix metalloproteinase and macrophage
  colony-stimulating factor serum concentrations in patients with head and neck
  cancer.
\newblock \emph{Neoplasma}, 51\penalty0 (5):\penalty0 375 -- 378, 2004.

\bibitem[Hoeben et~al.(2004)Hoeben, Landuyt, Highley, Wildiers, Oosterom, and
  Bruijn]{VEGF}
Ann Hoeben, Bart Landuyt, Martin~S. Highley, Hans Wildiers, Allan T.~Van
  Oosterom, and Ernst A.~De Bruijn.
\newblock Vascular endothelial growth factor and angiogenesis.
\newblock \emph{Pharmacological Reviews}, 56\penalty0 (4):\penalty0 549 -- 580,
  2004.

\bibitem[Brown and Wilson(2004)]{hypoxia}
J.~Martin Brown and William~R. Wilson.
\newblock Exploiting tumour hypoxia in cancer treatment.
\newblock \emph{Nature Review}, 4:\penalty0 437 -- 447, 2004.

\bibitem[Barsoum et~al.(2014)Barsoum, Smallwood, Siemens, and
  Graham]{hypoxia-9}
Ivraym~B. Barsoum, Chelsea~A. Smallwood, D.~Robert Siemens, and Charles~H.
  Graham.
\newblock A mechanism of hypoxia-mediated escape from adaptive immunity in
  cancer cells.
\newblock \emph{Cancer Research}, 74\penalty0 (3), 2014.

\bibitem[Patsoukis et~al.(2015)Patsoukis, Bardhan, Chatterjee, Sari, Liu, Bell,
  Karoly, Freeman, Petkova, Seth, Li, and Boussiotis]{PD-1}
Nikolaos Patsoukis, Kankana Bardhan, Pranam Chatterjee, Duygu Sari, Bianling
  Liu, Lauren~N. Bell, Edward~D. Karoly, Gordon~J. Freeman, Victoria Petkova,
  Pankaj Seth, Lequn Li, and Vassiliki~A. Boussiotis.
\newblock Pd-1 alters t-cell metabolic reprogramming by inhibiting glycolysis
  and promoting lipolysis and fatty acid oxidation.
\newblock \emph{Nature Communications}, 6\penalty0 (6692), 2015.

\bibitem[John et~al.(2013)John, h~Kershaw, and Darcy]{block}
Liza~B John, Michael h~Kershaw, and Phillip~K Darcy.
\newblock Blockade of pd-1 immunosuppression boosts car t-cell therapy.
\newblock \emph{Onco Immunology}, 2\penalty0 (10), 2013.

\bibitem[Chen et~al.(2018)Chen, Lin, Zhong, An, Lu, Yin, Liang, and
  McGowan]{knockout}
S~Chen, Y~Lin, S~Zhong, H~An, Y~Lu, M~Yin, W~Liang, and E~M McGowan.
\newblock Anti-muc1 car-t cells combined with pd-1 knockout engineered t cells
  for patients with non-small cell lung cancer (nsclc): A pilot study.
\newblock \emph{Annals of Oncology}, 29\penalty0 (10), 2018.

\bibitem[Denko(2008)]{hypoxia-3}
Nicholas~C. Denko.
\newblock Hypoxia, hif1 and glucose metabolism in the solid tumour.
\newblock \emph{Nature Reviews Cancer}, 8:\penalty0 705 -- 713, 2008.

\bibitem[RE and A.(2007)]{hypoxia-4}
Airley RE and Mobasheri A.
\newblock Hypoxic regulation of glucose transport, anaerobic metabolism and
  angiogenesis in cancer: novel pathways and targets for anticancer
  therapeutics.
\newblock \emph{Chemotherapy}, 53\penalty0 (4):\penalty0 233 -- 256, 2007.

\bibitem[Jacobs et~al.(2008)Jacobs, Herman, MacIver, Wofford, Wieman, Hammen,
  and Rathmell]{hypoxia-5}
Sarah~R. Jacobs, Catherine~E. Herman, Nancie~J. MacIver, Jessica~A. Wofford,
  Heather~L. Wieman, Jeremy~J. Hammen, and Jeffrey~C. Rathmell.
\newblock Glucose uptake is limiting in t cell activation and requires
  cd28-mediated akt-dependent and independent pathways.
\newblock \emph{The Journal of Immunology}, 180\penalty0 (7):\penalty0 4476 --
  4486, 2008.

\bibitem[Noman et~al.(2009)Noman, Buart, Pelt, Richon, Hasmim, Leleu,
  Suchorska, Jalil, Lecluse, Hage, Giuliani, Pichon, Azzarone, Mazure, Romero,
  Mami-Chouaib, and Chouaib]{hypoxia-6}
Muhammad~Zaeem Noman, Stéphanie Buart, Jos~Van Pelt, Catherine Richon, Meriem
  Hasmim, Nathalie Leleu, Wictoria~Maria Suchorska, Abdelali Jalil, Yann
  Lecluse, Faten~El Hage, Massimo Giuliani, Christophe Pichon, Bruno Azzarone,
  Nathalie Mazure, Pedro Romero, Fathia Mami-Chouaib, and Salem Chouaib.
\newblock The cooperative induction of hypoxia-inducible factor-1α and stat3
  during hypoxia induced an impairment of tumor susceptibility to ctl-mediated
  cell lysis.
\newblock \emph{The Journal of Immunology}, 182\penalty0 (6):\penalty0 3510 --
  3521, 2009.

\bibitem[Doedens et~al.(2013)Doedens, Phan, Stradner, Fujimoto, Nguyen, Yang,
  Johnson, and Goldrath]{hypoxia-7}
Andrew~L Doedens, Anthony~T Phan, Martin~H Stradner, Jessica~K Fujimoto,
  Jessica~V Nguyen, Edward Yang, Randall~S Johnson, and Ananda~W Goldrath.
\newblock Hypoxia-inducible factors enhance the effector responses of cd8+ t
  cells to persistent antigen.
\newblock \emph{Nature Immunology}, 14:\penalty0 1173 -- 1182, 2013.

\bibitem[Juillerat et~al.(2017)Juillerat, Marechal, Filhol, Valogne, Valton,
  Duclert, Duchateau, and Poirot]{hypoxia-8}
Alexandre Juillerat, Alan Marechal, Jean~Marie Filhol, Yannick Valogne, Julien
  Valton, Aymeric Duclert, Philippe Duchateau, and Laurent Poirot.
\newblock An oxygen sensitive self-decision making engineered car t-cell.
\newblock \emph{Scientific Reports}, 7:\penalty0 39833, 2017.

\bibitem[Schmidt et~al.(2012)Schmidt, Oberle, and Krammer]{Treg}
Angelika Schmidt, Nina Oberle, and Peter~H. Krammer.
\newblock Molecular mechanisms of treg-mediated t cell suppression.
\newblock \emph{Frontiers in Immunology}, 3\penalty0 (51), 2012.

\bibitem[Kang et~al.(2010)Kang, Xie, Ma, Liao, Zhang, and Luo]{Treg-2}
Shijun Kang, Jianmin Xie, Shudong Ma, Wangjun Liao, Junyi Zhang, and Rongcheng
  Luo.
\newblock Targeted knock down of ccl22 and ccl17 by sirna during dc
  differentiation and maturation affects the recruitment of t subsets.
\newblock \emph{Immunobiology}, 215\penalty0 (2):\penalty0 153 -- 162, 2010.

\bibitem[Curiel et~al.(2004)Curiel, Coukos, Zou, Alvarez, Cheng, Mottram,
  Evdemon-Hogan, Conejo-Garcia, Zhang, Burow, Zhu, and et. al]{Treg-3}
Tyler~J Curiel, George Coukos, Linhua Zou, Xavier Alvarez, Pui Cheng, Peter
  Mottram, Melina Evdemon-Hogan, Jose~R Conejo-Garcia, Lin Zhang, Matthew
  Burow, Yun Zhu, and Shuang~Wei et. al.
\newblock Specific recruitment of regulatory t cells in ovarian carcinoma
  fosters immune privilege and predicts reduced survival.
\newblock \emph{Nature Medicine}, 10:\penalty0 942 -- 949, 2004.

\bibitem[Facciabene et~al.(2011)Facciabene, Peng, Hagemann, Balint, Barchetti,
  Wang, Gimotty, Gilks, Lal, Zhang, and Coukos]{Treg-4}
Andrea Facciabene, Xiaohui Peng, Ian~S. Hagemann, Klara Balint, Andrea
  Barchetti, Li-Ping Wang, Phyllis~A. Gimotty, C.~Blake Gilks, Priti Lal, Lin
  Zhang, and George Coukos.
\newblock Tumour hypoxia promotes tolerance and angiogenesis via ccl28 and treg
  cells.
\newblock \emph{Nature}, 475:\penalty0 226 -- 230, 2011.

\bibitem[Tan et~al.(2009)Tan, Goedegebuure, Belt, Flaherty, Sankpal,
  Gillanders, Eberlein, Hsieh, and Linehan]{Treg-5}
Marcus C.~B. Tan, Peter~S. Goedegebuure, Brian~A. Belt, Brian Flaherty,
  Narendra Sankpal, William~E. Gillanders, Timothy~J. Eberlein, Chyi-Song
  Hsieh, and David~C. Linehan.
\newblock Disruption of ccr5-dependent homing of regulatory t cells inhibits
  tumor growth in a murine model of pancreatic cancer.
\newblock \emph{The Journal of Immunology}, 182\penalty0 (3):\penalty0 1746 --
  1755, 2009.

\bibitem[Lv et~al.(2014)Lv, Xu, Tang, Ren, Shen, Chen, Liu, Hou, and
  Wang]{Treg-6}
Mingming Lv, Yujun Xu, Ruijing Tang, Jing Ren, Sunan Shen, Yueqiu Chen, Baorui
  Liu, Yayi Hou, and Tingting Wang.
\newblock mir141–cxcl1–cxcr2 signaling–induced treg recruitment regulates
  metastases and survival of non–small cell lung cancer.
\newblock \emph{Molecular Cancer Therapeutics}, 13\penalty0 (12), 2014.

\bibitem[Whiteside et~al.(2011)Whiteside, Mandapathil, and Schuler]{Treg-7}
Theresa~L Whiteside, Magis Mandapathil, and P.~Schuler.
\newblock The role of the adenosinergic pathway in immunosuppression mediated
  by human regulatory t cells (treg).
\newblock \emph{Current Medicinal Chemistry}, 18, 2011.

\bibitem[Mandapathil and Whiteside(2011)]{Treg-8}
Magis Mandapathil and Theresa~L Whiteside.
\newblock Targeting human inducible regulatory t cells (tr1) in patients with
  cancer: blocking of adenosine–prostaglandin e2 cooperation.
\newblock \emph{Expert Opinion on Biological Therapy}, 11\penalty0 (9), 2011.

\bibitem[Insel et~al.(2012)Insel, Zhang, Murray, Yokouchi, and Zambon]{cAMP}
Paul~A. Insel, Lingzhi Zhang, Fiona Murray, Hiroshi Yokouchi, and Alexander~C.
  Zambon.
\newblock Cyclic amp is both a pro-apoptotic and anti-apoptotic second
  messenger.
\newblock \emph{Acta Physiologica}, 204\penalty0 (2), 2012.

\bibitem[Y.~Su(2011)]{cAMP-2}
E.~Gorelik Y.~Su, E.K.~Jackson.
\newblock Receptor desensitization and blockade of the suppressive effects of
  prostaglandin e(2) and adenosine on the cytotoxic activity of human
  melanoma-infiltrating t lymphocytes.
\newblock \emph{Cancer Immunology}, 60, 2011.

\bibitem[Hoskin et~al.(2008)Hoskin, Mader, Furlong, and D.M.~Conrad]{cAMP-3}
D.W. Hoskin, J.S. Mader, S.J. Furlong, and J.~Blay D.M.~Conrad.
\newblock Inhibition of t cell and natural killer cell function by adenosine
  and its contribution to immune evasion by tumor cells (review).
\newblock \emph{International Journal of Oncology}, 32, 2008.

\bibitem[Brudvik and Tasken(2012)]{cAMP-4}
K.W. Brudvik and K.~Tasken.
\newblock Modulation of t cell immune functions by the prostaglandin e(2) –
  camp pathway in chronic inflammatory states.
\newblock \emph{British Journal of Pharmacology}, 166, 2012.

\bibitem[Hussaina et~al.(2013)Hussaina, Javeeda, Ashraf, Yuzhu, and
  Mukhtar]{cAMP-5}
Muzammal Hussaina, Aqeel Javeeda, Muhammad Ashraf, Hou Yuzhu, and
  Muhammad~Mahmood Mukhtar.
\newblock Multilevel pharmacological manipulation of adenosine–prostaglandin
  e2/camp nexus in the tumor microenvironment: A ‘two hit’ therapeutic
  opportunity.
\newblock \emph{Pharmacological Research}, 73, 2013.

\bibitem[K et~al.(2016)K, S, J, V, S, A, E, E, and SM]{cAMP-6}
Newick K, O'Brien S, Sun J, Kapoor V, Maceyko S, Lo~A, Puré E, Moon E, and
  Albelda SM.
\newblock Augmentation of car t-cell trafficking and antitumor efficacy by
  blocking protein kinase a localization.
\newblock \emph{Cancer Immunology Research}, 4\penalty0 (6), 2016.

\bibitem[N and Aandahl(2016)]{ezrin}
Kjetil~Taske´ N and Einar~Martin Aandahl.
\newblock Localized effects of camp mediated by distinct routes of protein
  kinase a.
\newblock \emph{Physiological Reviews}, 84\penalty0 (1), 2016.

\bibitem[Jarnæss and Taskén(2007)]{ezrin-2}
E.~Jarnæss and K.~Taskén.
\newblock Spatiotemporal control of camp signalling processes by anchored
  signalling complexes.
\newblock \emph{Biochemical Society Transactions}, 35\penalty0 (5), 2007.

\bibitem[Sassone-Corsi(2012)]{PKA}
Paolo Sassone-Corsi.
\newblock The cyclic amp pathway.
\newblock \emph{Cold Spring Harbor Perspectives in Biology}, 4\penalty0 (12),
  2012.

\bibitem[McGranahan and Swanton(2017)]{heterogeneity}
Nicholas McGranahan and Charles Swanton.
\newblock Clonal heterogeneity and tumor evolution: Past, present, and the
  future.
\newblock \emph{Cell}, 168\penalty0 (4), 2017.

\bibitem[Ashford et~al.(2019)Ashford, Pang, Moya-García, Adeyelu, and
  Orengo]{CATH}
Paul Ashford, Camilla S.~M. Pang, Aurelio~A. Moya-García, Tolulope Adeyelu,
  and Christine~A. Orengo.
\newblock A cath domain functional family based approach to identify putative
  cancer driver genes and driver mutations.
\newblock \emph{Scientific Reports}, 9\penalty0 (263), 2019.

\bibitem[chao Feng et~al.(2017)chao Feng, lei Guo, Liu, ren Dai, Wang, yan Lv,
  hua Huang, ming Yang, and dong Han]{CRS-2}
Kai chao Feng, Ye~lei Guo, Yang Liu, Han ren Dai, Yao Wang, Hai yan Lv, Jian
  hua Huang, Qing ming Yang, and Wei dong Han.
\newblock Cocktail treatment with egfr-specific and cd133-specific chimeric
  antigen receptor-modified t cells in a patient with advanced
  cholangiocarcinoma.
\newblock \emph{Journal of Hematology \& Oncology}, 10\penalty0 (4), 2017.

\bibitem[Ahmed et~al.(2015)Ahmed, Brawley, Hegde, Robertson, Ghazi, Gerken,
  Liu, Dakhova, Ashoori, Corder, Gray, and Wu]{CRS-3}
Nabil Ahmed, Vita~S. Brawley, Meenakshi Hegde, Catherine Robertson, Alexia
  Ghazi, Claudia Gerken, Enli Liu, Olga Dakhova, Aidin Ashoori, Amanda Corder,
  Tara Gray, and Meng-Fen Wu.
\newblock Human epidermal growth factor receptor 2 (her2) –specific chimeric
  antigen receptor–modified t cells for the immunotherapy of her2-positive
  sarcoma.
\newblock \emph{Journal of Clinical Oncology}, 33\penalty0 (15), 2015.

\bibitem[Lamers et~al.(2013)Lamers, Sleijfer, van Steenbergen, van Elzakker,
  van Krimpen, Groot, Vulto, den Bakker, Oosterwijk, Debets, and
  Gratama]{on-target}
Cor~HJ Lamers, Stefan Sleijfer, Sabine van Steenbergen, Pascal van Elzakker,
  Brigitte van Krimpen, Corrien Groot, Arnold Vulto, Michael den Bakker, Egbert
  Oosterwijk, Reno Debets, and Jan~W Gratama.
\newblock Treatment of metastatic renal cell carcinoma with caix car-engineered
  t cells: Clinical evaluation and management of on-target toxicity.
\newblock \emph{Molecular Therapy}, 21\penalty0 (4), 2013.

\bibitem[Morgan et~al.(2010)Morgan, Yang, Kitano, Dudley, Laurencot, and
  Rosenberg]{fatal}
Richard~A Morgan, James~C Yang, Mio Kitano, Mark~E Dudley, Carolyn~M Laurencot,
  and Steven~A Rosenberg.
\newblock Case report of a serious adverse event following the administration
  of t cells transduced with a chimeric antigen receptor recognizing erbb2.
\newblock \emph{Molecular Therapy}, 18\penalty0 (4), 2010.

\bibitem[JT et~al.(2018)JT, X, J, V, CL, J, IH, SH, AA, AR, BC, and
  et.al]{organoid}
Neal JT, Li~X, Zhu J, Giangarra V, Grzeskowiak CL, Ju~J, Liu IH, Chiou SH,
  Salahudeen AA, Smith AR, Deutsch BC, and Liao~L et.al.
\newblock Organoid modeling of the tumor immune microenvironment.
\newblock \emph{Cell}, 175, 2018.

\bibitem[F et~al.(2017)F, SH, RK, J, J, M, RC, CW, and M]{trans}
Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, Hendrickson
  RC, Brennan CW, and Sadelain M.
\newblock Integrating proteomics and transcriptomics for systematic
  combinatorial chimeric antigen receptor therapy of aml.
\newblock \emph{Cancer Cell}, 32, 2017.

\bibitem[Salter et~al.(2018)Salter, Ivey, Kennedy, Voillet, Rajan, Alderman,
  Voytovich, Lin, Sommermeyer, Liu, Whiteaker, Gottardo, Paulovich, and
  Riddell]{trans-2}
Alexander~I. Salter, Richard~G. Ivey, Jacob~J. Kennedy, Valentin Voillet,
  Anusha Rajan, Eva~J. Alderman, Uliana~J. Voytovich, Chenwei Lin, Daniel
  Sommermeyer, Lingfeng Liu, Jeffrey~R. Whiteaker, Raphael Gottardo, Amanda~G.
  Paulovich, and Stanley~R. Riddell.
\newblock Phosphoproteomic analysis of chimeric antigen receptor signaling
  reveals kinetic and quantitative differences that affect cell function.
\newblock \emph{Science Signaling}, 11, 2018.

\end{thebibliography}
